Detecting Immune Cells in Cancer Patients' Blood
Author Information
Author(s): Maeda Y, Hida N, Niiya F, Katagiri K, Harada M, Yamana H, Kamura T, Takahashi M, Sato Y, Todo S, Itoh K
Primary Institution: Kurume University
Hypothesis
Can peptide-specific cytotoxic T lymphocyte precursors be detected in the blood of cancer patients before vaccination?
Conclusion
Peptide-specific cytotoxic T lymphocyte precursors are detectable in the majority of cancer patients prior to vaccination.
Supporting Evidence
- 71% of cancer patients had detectable CTL-precursors in their blood.
- The mean number of positive peptides per patient was 2.0.
- PBMCs incubated with positive peptides showed significant cytotoxicity to cancer cells.
Takeaway
Doctors can find special immune cells in the blood of cancer patients that can help fight cancer before they get a vaccine.
Methodology
Peripheral blood mononuclear cells were isolated from cancer patients and tested for reactivity to various peptides to detect CTL-precursors.
Potential Biases
Potential bias due to the selection of patients and the limited number of peptides tested.
Limitations
The study did not assess the correlation between CTL-precursor detection and antigen expression in individual cancer patients.
Participant Demographics
80 cancer patients (40 gastric, 15 colon, 11 lung, 7 gynecological, 3 prostate, and 4 melanoma) and 31 healthy volunteers.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website